Stifel Nicolaus Keeps Their Buy Rating on Rhythm Pharmaceuticals (RYTM)

Stifel Nicolaus analyst Derek Archila reiterated a Buy rating on Rhythm Pharmaceuticals (RYTMResearch Report) today. The company’s shares closed last Friday at $22.92.

According to TipRanks.com, Archila is a 4-star analyst with an average return of 8.8% and a 45.4% success rate. Archila covers the Healthcare sector, focusing on stocks such as DBV Technologies SA – American, Madrigal Pharmaceuticals, and Phasebio Pharmaceuticals.

Currently, the analyst consensus on Rhythm Pharmaceuticals is a Strong Buy with an average price target of $38.67.

See today’s analyst top recommended stocks >>

Based on Rhythm Pharmaceuticals’ latest earnings release for the quarter ending June 30, the company reported a quarterly GAAP net loss of $31.12 million. In comparison, last year the company had a GAAP net loss of $42.8 million.

Based on the recent corporate insider activity of 31 insiders, corporate insider sentiment is neutral on the stock.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Rhythm Pharmaceuticals, Inc. develops and commercializes peptide therapeutics for the treatment of gastrointestinal diseases and genetic deficiencies. It focuses on the treatment for Prader-Willi Syndrome and Pro-Opiomelanocortin deficiency obesity. The firm rapidly develops setmelanotide for rare genetic disorders of obesity caused by MC4 pathway deficiencies and provides advance setmelanotide for POMC deficiency obesity and LEPR deficiency obesity as first indications in upstream MC4 pathway deficiencies. The company was founded by Bart Henderson in February 2010 and is headquartered in Boston, MA.